Real‐world effectiveness of brentuximab vedotin in the treatment of CD30‐positive cutaneous T‐cell lymphoma: a single‐centre retrospective review

Abstract

of nutrients and oxygenation. It amplifies the migration of epithelial cells from the surrounding skin and thereby augments fibroblastic growth and epithelialization. 5,7,8 These factors in turn may help to counteract the clinicopathological basis of venous stasis.A literature search did not reveal any relevant data on the use of citric acid for patients with eczema. To the best of our knowledge, this is the first report where citric acid was used for the treatment of infected venous eczema with a positive outcome. We propose this novel technique, which will open up new avenues for research into this safe and cost-effective approach for treatment of infected venous eczema refractory to conventional approaches.

Brentuximab vedotin in the treatment of cutaneous T‐cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry

“…In addition, we observed a high rate of CR in patients with FMF (Figure 2a–d), a variant of MF that due to the deep location of the infiltrate, is considered particularly resistant to skin‐directed therapies. Although in the ALCANZA trial, no specific information about this MF variant was given, 1 our results agree with recent observations and suggest that BV may be an effective option in FMF 9,14 …”

“…Although in the ALCANZA trial, no specific information about this MF variant was given, 1 our results agree with recent observations and suggest that BV may be an effective option in FMF. 9,14 Looking at the CD30 LPD, in this study we included 10 pcALCL and 2 LyP. Eight of the 10 pcALCL patients had advanced stages with extracutaneous involvement.…”

Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: data from the Spanish Primary Cutaneous Lymphoma Registry

“…2a-d), a variant of MF that due to the deep location of the infiltrate, is considered particularly resistant to skin-directed therapies. Although in the ALCANZA trial no specific information about this MF variant was given 1 , our results agree with recent observations and suggest that BV may be an effective option in FMF 9,14 .…”

Anti-CD30 antibody–drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives

“…Real-world studies on brentuximab vedotin therapy for CTCL support the results of the ALCANZA trial, with good responses to treatment observed in patients with MF and C-ALCL [ 94 – 98 ] and provide evidence for potential benefits of brentuximab vedotin in other CTCL subtypes [ 94 , 98 – 101 ]. A European retrospective study in patients with MF and SS did not detect any differences in response by CD30 level or previous treatment, but suggested a potential association between lower disease stage and higher ORR4, as well as between LCT and skin ORR [ 96 ].…”

“…The aforementioned European study in patients with MF and SS did not detect any difference in treatment response between these two subtypes, suggesting that patients with SS can benefit from brentuximab vedotin treatment to a similar extent as MF patients [ 96 ]. Cases studies in patients with refractory primary cutaneous gamma-delta T-cell lymphoma have also noted benefits of brentuximab vedotin treatment [ 100 , 101 ], and some retrospective studies of brentuximab vedotin for CTCL have included a range of different rare subtypes, noting treatment responses in folliculotropic MF, SS with LCT, and granulomatous MF [ 94 , 98 ].…”